939 related articles for article (PubMed ID: 32019317)
21. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.
Breen ID; Brumfiel CM; Patel MH; Butterfield RJ; VanderPluym JH; Griffing L; Pittelkow MR; Mangold AR
JAMA Netw Open; 2021 Apr; 4(4):e217934. PubMed ID: 33871613
[TBL] [Abstract][Full Text] [Related]
22. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
23. A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine.
Reuter U
Headache; 2018 May; 58 Suppl 1():48-59. PubMed ID: 29697156
[TBL] [Abstract][Full Text] [Related]
24. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
Dodick DW
Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
[TBL] [Abstract][Full Text] [Related]
25. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
26. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
27. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
Raffaelli B; Reuter U
Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
[TBL] [Abstract][Full Text] [Related]
28. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
Levin M; Silberstein SD; Gilbert R; Lucas S; Munsie L; Garrelts A; Kennedy K; Everman N; Pearlman E
Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
30. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
Kielbasa W; Helton DL
Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
[TBL] [Abstract][Full Text] [Related]
31. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
Sevivas H; Fresco P
Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
[TBL] [Abstract][Full Text] [Related]
32. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
Khan S; Olesen A; Ashina M
Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
[TBL] [Abstract][Full Text] [Related]
33. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
[TBL] [Abstract][Full Text] [Related]
35. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
Yuan H; White CS; Silberstein SD
Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
[TBL] [Abstract][Full Text] [Related]
36. Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review.
Tfelt-Hansen P; Diener HC; Steiner TJ
Cephalalgia; 2020 Jan; 40(1):122-126. PubMed ID: 31547694
[TBL] [Abstract][Full Text] [Related]
37. Role of CGRP in Migraine.
Edvinsson L
Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
[TBL] [Abstract][Full Text] [Related]
38. Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions.
Janković SM; Janković SV
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):263-275. PubMed ID: 38457093
[TBL] [Abstract][Full Text] [Related]
39. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.
Szperka CL; VanderPluym J; Orr SL; Oakley CB; Qubty W; Patniyot I; Lagman-Bartolome AM; Morris C; Gautreaux J; Victorio MC; Hagler S; Narula S; Candee MS; Cleves-Bayon C; Rao R; Fryer RH; Bicknese AR; Yonker M; Hershey AD; Powers SW; Goadsby PJ; Gelfand AA
Headache; 2018 Nov; 58(10):1658-1669. PubMed ID: 30324723
[No Abstract] [Full Text] [Related]
40. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis.
Alasad YW; Asha MZ
Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
